Brittany M. Ashlock, Ph.D.
Affiliations: | 2012 | Microbiology and Immunology (Medicine) | University of Miami, Coral Gables, FL |
Area:
Microbiology Biology, OncologyGoogle:
"Brittany Ashlock"Parents
Sign in to add mentor| Enrique A. Mesri | grad student | 2012 | University of Miami | |
| (Characterization and validation of preclinical models of KSHV-induced malignancies to elucidate antineoplastic and antiviral therapeutic approaches.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ashlock BM, Ma Q, Issac B, et al. (2014) Productively infected murine Kaposi's sarcoma-like tumors define new animal models for studying and targeting KSHV oncogenesis and replication. Plos One. 9: e87324 |
| Bayraktar UD, Diaz LA, Ashlock B, et al. (2014) Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas. Leukemia & Lymphoma. 55: 786-94 |
| Mesri EA, Cavallin LE, Ashlock BM, et al. (2013) Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis. Immunologic Research. 57: 159-65 |
| Bhatt S, Ashlock BM, Natkunam Y, et al. (2013) CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 122: 1233-42 |
| Bhatt S, Ashlock BM, Toomey NL, et al. (2013) Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. The Journal of Clinical Investigation. 123: 2616-28 |
| Daftarian P, Chowdhury R, Ames P, et al. (2011) In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations. Hybridoma (2005). 30: 409-18 |
| Bhatt S, Ashlock B, Natkunam Y, et al. (2011) Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL), Blood. 118: 3728-3728 |
| Bhatt S, Ashlock B, Toomey N, et al. (2011) Synergistic Preclinical Activity of Bortezomib with Suberoylanilide Hydroxamic Acid (SAHA) in Primary Effusion Lymphoma (PEL) Blood. 118: 1650-1650 |
| Schmidt B, Ashlock BM, Foster H, et al. (2005) HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology. 343: 256-66 |
| Schmidt B, Ashlock B, Neipel F, et al. (2004) Potential screening assay for undetectable viruses on the basis of their capacity to induce alpha interferon production. Journal of Clinical Microbiology. 42: 4300-2 |